Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
3.09M | 2.07M | 144.00K | 0.00 | 0.00 | Gross Profit |
-62.77M | -3.12M | -1.24M | -1.15M | -794.00K | EBIT |
-100.26M | -102.77M | -66.03M | -28.64M | -17.34M | EBITDA |
-93.49M | -97.58M | -64.64M | -27.50M | -16.55M | Net Income Common Stockholders |
-97.43M | -102.64M | -69.16M | -30.20M | -18.53M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
73.43M | 70.61M | 225.33M | 22.95M | 2.27M | Total Assets |
204.37M | 146.00M | 233.33M | 28.08M | 6.12M | Total Debt |
128.43M | 22.58M | 19.87M | 11.73M | 11.89M | Net Debt |
59.98M | -48.03M | -166.61M | -11.22M | 9.62M | Total Liabilities |
146.35M | 40.03M | 32.70M | 92.71M | 42.04M | Stockholders Equity |
58.02M | 105.97M | 200.63M | -64.63M | -35.92M |
Cash Flow | Free Cash Flow | |||
-94.38M | -99.89M | -59.08M | -27.94M | -16.56M | Operating Cash Flow |
-91.51M | -98.52M | -57.61M | -26.13M | -15.68M | Investing Cash Flow |
47.52M | -18.06M | -40.40M | -1.81M | -885.00K | Financing Cash Flow |
41.82M | 708.00K | 261.54M | 48.62M | 11.98M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% | |
50 Neutral | $3.30B | ― | -19.20% | ― | -89.95% | -123.71% | |
48 Neutral | $462.65M | ― | -36.36% | ― | 174.98% | 25.06% | |
45 Neutral | $2.04B | ― | -43.94% | ― | -83.18% | -144.95% | |
41 Neutral | $2.11M | ― | -166.90% | ― | 184.93% | 36.45% | |
39 Underperform | $915.09M | ― | -54.00% | ― | 59.55% | 3.09% | |
33 Underperform | $137.28M | ― | -98.10% | ― | -58.64% | -40.05% |
On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello resigned from the Board of Directors of Omega Therapeutics. Subsequently, on January 24, 2025, Jeffrey T. Varsalone was appointed as a Class I director, receiving a monthly cash fee and indemnification as part of his agreement with the company. Additionally, Richard Kender was moved from Class III to Class II in order to rebalance the board’s classes, with his service deemed uninterrupted for all purposes.
Michelle C. Werner has resigned from Omega Therapeutics’ Board of Directors and the Nominating and Corporate Governance Committee, effective immediately. The company has also received a non-binding proposal from Mirai Bio, Inc. to take over Omega’s rights and obligations under a collaboration agreement with Novo Nordisk and related entities. This proposal involves Mirai assuming $8 million of Omega’s debt, and the company’s Board has formed a special committee to evaluate the offer and explore strategic alternatives.
Omega Therapeutics, Inc. has appointed Ravi Mehrotra, Ph.D., as a Class II director, replacing John Mendlein, Ph.D. and Richard A. Young, Ph.D. Mehrotra will receive an annual retainer and stock options as part of the Non-Employee Director Compensation Program. His stock options will vest over three years, ensuring alignment with the company’s long-term growth strategy. This leadership change reflects Omega’s strategic focus on innovation and development without any underlying personal or financial conflicts.
Omega Therapeutics has revamped its shared space arrangements with several affiliates, and announced leadership changes with Kaan Certel stepping in as CEO following Mahesh Karande’s resignation. These moves come alongside ambitious plans to advance their pioneering epigenomic medicines platform, aiming to address a wide range of diseases. Omega is actively pursuing strategic partnerships to bolster their pipeline, positioning themselves as leaders in the development of programmable epigenomic therapies, signaling to investors a potential for significant growth and innovation in the biopharmaceutical market.